Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:REGN
- CUSIP: 75886F10
- Web: www.regeneron.com
Capitalization:- Market Cap: $45.99381 billion
- Outstanding Shares: 106,033,000
Average Prices:- 50 Day Moving Avg: $468.97
- 200 Day Moving Avg: $447.18
- 52 Week Range: $325.35 - $543.55
P/E:- Trailing P/E Ratio: 43.94
- Foreward P/E Ratio: 30.13
- P/E Growth: 1.61
Sales & Book Value:- Annual Revenue: $5.24 billion
- Price / Sales: 8.87
- Book Value: $52.07 per share
- Price / Book: 8.41
Profitability:- EBIDTA: $1.82 billion
- Net Margins: 22.05%
- Return on Equity: 25.58%
- Return on Assets: 16.63%
Debt:- Debt-to-Equity Ratio: 0.13%
- Current Ratio: 3.75%
- Quick Ratio: 3.21%
Misc:- Average Volume: 845,638 shs.
- Beta: 1.65
- Short Ratio: 3.33
Frequently Asked Questions for Regeneron Pharmaceuticals (NASDAQ:REGN)
What is Regeneron Pharmaceuticals' stock symbol?
Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its earnings results on Thursday, August, 3rd. The company reported $4.17 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $2.67 by $1.50. The firm earned $1.47 billion during the quarter, compared to analysts' expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company's revenue was up 21.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.82 earnings per share. View Regeneron Pharmaceuticals' Earnings History.
When will Regeneron Pharmaceuticals make its next earnings announcement?
Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?
25 brokers have issued twelve-month price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $345.00 to $605.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $492.82 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.
What are analysts saying about Regeneron Pharmaceuticals stock?
Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Regeneron’s second-quarter results were impressive as both earnings and sales beat estimates on the back of strong Eylea sales which grabbed additional market share. Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The increase in guidance was also encouraging. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and the company is working to expand its label. A potential approval of the drug in the EU in the second half will further boost sales. Further, the approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU has boosted the company’s portfolio. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress." (8/9/2017)
- 2. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
- 3. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
- 4. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Axovant Sciences Ltd (AXON), Prothena Corporation PLC (PRTA) and China Biologic Products (CBPO).
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the folowing people:
- P. Roy Vagelos M.D., Chairman of the Board
- Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
- Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
- Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
- Neil Stahl Ph.D., Executive Vice President - Research and Development
- Robert J. Terifay, Executive Vice President - Commercial
- Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
- Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
- Peter Powchik M.D., Senior Vice President - Clinical Development
- George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director
Who owns Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.67%), Capital World Investors (6.54%), BlackRock Inc. (5.86%), Vanguard Group Inc. (4.99%), State Street Corp (3.10%) and Artisan Partners Limited Partnership (1.86%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.
Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Southpoint Capital Advisors LP, Capital World Investors, Bank of New York Mellon Corp, State Street Corp, Manning & Napier Advisors LLC, BB Biotech AG, Ameriprise Financial Inc. and Rockefeller Financial Services Inc.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.
Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, FMR LLC, TIAA CREF Investment Management LLC, PointState Capital LP, Vanguard Group Inc., Teachers Advisors LLC and Polen Capital Management LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.
How do I buy Regeneron Pharmaceuticals stock?
Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regeneron Pharmaceuticals' stock price today?
One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $438.11.
MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 13 Hold Ratings, 11 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.40) |
| Consensus Price Target: | $492.82 (12.49% upside) |
Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/14/2017 | Royal Bank Of Canada | Initiated Coverage | Sector Perform -> Sector Perform | $475.00 | Medium |  |
| 9/11/2017 | Canaccord Genuity | Reiterated Rating | Buy | $522.00 | Low | |
| 9/11/2017 | Credit Suisse Group | Reiterated Rating | Buy | $485.00 | Low | |
| 9/8/2017 | Robert W. Baird | Reiterated Rating | Sell | $408.00 | Low | |
| 9/7/2017 | Citigroup Inc. | Reiterated Rating | Buy | $575.00 | Low | |
| 9/6/2017 | Raymond James Financial, Inc. | Reiterated Rating | Outperform -> Outperform | $566.00 | Low | |
| 8/23/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $450.00 | Low | |
| 8/16/2017 | Evercore ISI | Initiated Coverage | Outperform -> Outperform | $605.00 | Medium | |
| 8/15/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | | Low | |
| 8/15/2017 | Leerink Swann | Reiterated Rating | Outperform -> Positive | $580.00 -> $552.00 | Low | |
| 8/9/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $418.00 -> $471.00 | Low | |
| 8/9/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $469.00 -> $472.00 | Low | |
| 8/3/2017 | BMO Capital Markets | Set Price Target | Hold | $491.00 | Low | |
| 8/1/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $557.00 | High | |
| 7/22/2017 | Barclays PLC | Reiterated Rating | Equal Weight | $400.00 -> $450.00 | Low | |
| 7/21/2017 | Bank of America Corporation | Reiterated Rating | Buy | $589.00 -> $593.00 | Low | |
| 6/30/2017 | BTIG Research | Reiterated Rating | Buy -> Buy | $480.00 -> $540.00 | High | |
| 6/26/2017 | Sanford C. Bernstein | Downgrade | Outperform -> Market Perform | $410.00 -> $480.00 | Low | |
| 6/14/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | Low | |
| 5/15/2017 | Cowen and Company | Reiterated Rating | Hold | $380.00 | Low | |
| 3/17/2017 | CIBC | Initiated Coverage | Market Perform -> Market Perform | | Low | |
| 1/10/2017 | Wells Fargo & Company | Reiterated Rating | Market Perform | | N/A | |
| 1/6/2017 | Chardan Capital | Lower Price Target | Neutral | $350.00 -> $345.00 | N/A | |
| 12/28/2016 | Argus | Reiterated Rating | Buy | $450.00 | N/A | |
| 10/28/2016 | Roth Capital | Set Price Target | Buy | $520.00 | N/A | |
| 8/5/2016 | Brean Capital | Reiterated Rating | Buy | $489.00 | N/A | |
| 3/17/2016 | SunTrust Banks, Inc. | Lower Price Target | Neutral | $450.00 -> $410.00 | N/A | |
| 3/15/2016 | Gabelli | Initiated Coverage | Buy | $574.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)Earnings History by Quarter for Regeneron Pharmaceuticals (NASDAQ REGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | $3.83 | | | | | N/A | |
| 8/3/2017 | Q2 2017 | $2.67 | $4.17 | $1.36 billion | $1.47 billion | View | Listen | |
| 5/4/2017 | Q1 2017 | $2.50 | $2.92 | $1.30 billion | $1.32 billion | View | Listen | |
| 2/9/2017 | Q4 2016 | $3.03 | $3.04 | $1.30 billion | $1.23 billion | View | Listen | |
| 11/4/2016 | Q316 | $2.73 | $3.13 | $1.29 billion | $1.22 billion | View | N/A | |
| 8/4/2016 | Q216 | $2.65 | $2.82 | $1.24 billion | $1.21 billion | View | N/A | |
| 5/5/2016 | Q116 | $2.58 | $2.57 | $1.18 billion | $1.20 billion | View | N/A | |
| 2/9/2016 | Q415 | $3.40 | $2.83 | $1.17 billion | $1.10 billion | View | Listen | |
| 11/4/2015 | Q315 | $2.62 | $3.47 | $1.05 billion | $1.14 billion | View | Listen | |
| 8/4/2015 | Q215 | $2.77 | $2.89 | $887.03 million | $999.00 million | View | Listen | |
| 5/7/2015 | Q115 | $2.50 | $2.88 | $820.30 million | $870.00 million | View | N/A | |
| 2/10/2015 | Q414 | $2.78 | $2.79 | $775.42 million | $802.00 million | View | N/A | |
| 11/4/2014 | Q314 | $2.57 | $2.52 | $733.04 million | $726.00 million | View | N/A | |
| 8/5/2014 | Q214 | $2.30 | $2.47 | $647.99 million | $666.00 million | View | N/A | |
| 5/8/2014 | Q114 | $0.94 | $0.58 | $609.04 million | $626.00 million | View | N/A | |
| 2/11/2014 | Q413 | $0.97 | $2.24 | $579.17 million | $610.00 million | View | N/A | |
| 11/5/2013 | Q313 | $0.92 | $2.40 | $501.93 million | $597.00 million | View | N/A | |
| 8/6/2013 | Q2 2013 | $0.92 | $1.73 | $470.63 million | $458.00 million | View | N/A | |
| 5/3/2013 | Q1 2013 | $1.46 | $1.78 | $424.26 million | $440.00 million | View | N/A | |
| 2/14/2013 | Q4 2012 | $1.11 | $1.47 | $392.64 million | $415.00 million | View | N/A | |
| 10/24/2012 | | $1.14 | $1.89 | | | View | N/A | |
| 7/25/2012 | | $0.45 | $0.90 | | | View | N/A | |
| 4/26/2012 | | ($0.33) | $0.37 | | | View | N/A | |
| 2/13/2012 | | ($0.60) | ($0.37) | | | View | N/A | |
| 7/28/2011 | | ($0.40) | ($0.69) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)Current Year EPS Consensus Estimate: $13.81 EPS
Next Year EPS Consensus Estimate: $14.54 EPS
Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Regeneron Pharmaceuticals (NASDAQ:REGN)Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 67.94%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/6/2017 | Robert E Landry | SVP | Sell | 663 | $498.60 | $330,571.80 | |
| 9/5/2017 | Robert E Landry | CFO | Sell | 189 | $501.06 | $94,700.34 | |
| 8/31/2017 | Robert E Landry | SVP | Sell | 427 | $493.43 | $210,694.61 | |
| 8/25/2017 | Sanofi | Major Shareholder | Buy | 72,378 | $481.36 | $34,839,874.08 | |
| 8/24/2017 | Sanofi | Major Shareholder | Buy | 166,415 | $480.93 | $80,033,965.95 | |
| 8/23/2017 | Robert E Landry | SVP | Sell | 468 | $476.45 | $222,978.60 | |
| 8/22/2017 | P Roy Vagelos | Chairman | Sell | 56,213 | $474.48 | $26,671,944.24 | |
| 8/18/2017 | P Roy Vagelos | Chairman | Sell | 15,191 | $470.15 | $7,142,048.65 | |
| 8/17/2017 | P Roy Vagelos | Chairman | Sell | 1,305 | $470.00 | $613,350.00 | |
| 8/16/2017 | P Roy Vagelos | Chairman | Sell | 10,986 | $470.17 | $5,165,287.62 | |
| 8/8/2017 | Robert E Landry | SVP | Sell | 526 | $472.19 | $248,371.94 | |
| 6/22/2017 | Michael S Aberman | SVP | Sell | 2,269 | $532.42 | $1,208,060.98 | |
| 6/22/2017 | Neil Stahl | EVP | Sell | 8,306 | $532.55 | $4,423,360.30 | |
| 6/20/2017 | Michael S Brown | Director | Sell | 3,000 | $500.00 | $1,500,000.00 | |
| 6/16/2017 | Robert J Terifay | EVP | Sell | 21,147 | $468.19 | $9,900,813.93 | |
| 6/15/2017 | Neil Stahl | EVP | Sell | 8,567 | $468.45 | $4,013,211.15 | |
| 6/9/2017 | Joseph L Goldstein | Director | Sell | 1,000 | $482.55 | $482,550.00 | |
| 6/2/2017 | Neil Stahl | EVP | Sell | 2,812 | $479.49 | $1,348,325.88 | |
| 6/2/2017 | Sanofi | Major Shareholder | Buy | 136,050 | $478.17 | $65,055,028.50 | |
| 5/25/2017 | P Roy Vagelos | Chairman | Sell | 9,295 | $458.14 | $4,258,411.30 | |
| 5/12/2017 | Michael S Brown | Director | Sell | 3,000 | $450.00 | $1,350,000.00 | |
| 3/29/2017 | Michael S Brown | Director | Sell | 1,000 | $400.00 | $400,000.00 | |
| 1/11/2017 | Sanofi | Major Shareholder | Buy | 87,298 | $369.71 | $32,274,943.58 | |
| 12/12/2016 | Charles A Baker | Director | Sell | 3,000 | $392.02 | $1,176,060.00 | |
| 11/15/2016 | Arthur F Ryan | Director | Sell | 2,000 | $429.34 | $858,680.00 | |
| 11/14/2016 | Joseph L Goldstein | Director | Sell | 2,125 | $450.00 | $956,250.00 | |
| 7/29/2016 | Joseph L Goldstein | Director | Sell | 2,125 | $425.00 | $903,125.00 | |
| 6/14/2016 | Sanofi | Major Shareholder | Buy | 64,731 | $363.86 | $23,553,021.66 | |
| 5/24/2016 | Arthur F Ryan | Director | Sell | 1,000 | $396.64 | $396,640.00 | |
| 5/18/2016 | Plew Daniel P Van | EVP | Sell | 4,413 | $385.77 | $1,702,403.01 | |
| 4/6/2016 | Joseph L Goldstein | Director | Sell | 2,000 | $425.00 | $850,000.00 | |
| 3/21/2016 | Joseph L Goldstein | Director | Sell | 2,000 | $375.00 | $750,000.00 | |
| 2/17/2016 | Sanofi | Major Shareholder | Buy | 161,157 | $392.46 | $63,247,676.22 | |
| 1/12/2016 | Sanofi | Major Shareholder | Buy | 83,938 | $465.04 | $39,034,527.52 | |
| 12/29/2015 | Douglas S. Mccorkle | VP | Sell | 3,954 | $552.08 | $2,182,924.32 | |
| 12/10/2015 | Michael S. Brown | Director | Sell | 3,000 | $546.45 | $1,639,350.00 | |
| 12/2/2015 | George Yancopoulos | insider | Sell | 43,348 | $549.03 | $23,799,352.44 | |
| 11/18/2015 | P Roy Vagelos | Chairman | Sell | 17,240 | $587.90 | $10,135,396.00 | |
| 11/10/2015 | Plew Daniel P. Van | SVP | Sell | 5,123 | $554.85 | $2,842,496.55 | |
| 11/9/2015 | Neil Stahl | EVP | Sell | 42,101 | $561.45 | $23,637,606.45 | |
| 11/3/2015 | P Roy Vagelos | Chairman | Sell | 17,242 | $580.19 | $10,003,635.98 | |
| 11/2/2015 | George Yancopoulos | insider | Sell | 43,348 | $571.61 | $24,778,150.28 | |
| 10/6/2015 | Sanofi | Major Shareholder | Buy | 80,538 | $459.71 | $37,024,123.98 | |
| 9/23/2015 | Sanofi | Major Shareholder | Buy | 147,209 | $534.67 | $78,708,236.03 | |
| 9/21/2015 | Michael S. Brown | Director | Sell | 3,000 | $551.55 | $1,654,650.00 | |
| 9/17/2015 | Charles A. Baker | Director | Sell | 5,000 | $550.00 | $2,750,000.00 | |
| 8/14/2015 | Peter Powchik | SVP | Sell | 23,485 | $573.38 | $13,465,829.30 | |
| 7/15/2015 | Joseph L Goldstein | Director | Sell | 2,000 | $550.00 | $1,100,000.00 | |
| 6/22/2015 | Joseph L Goldstein | Director | Sell | 2,000 | $526.85 | $1,053,700.00 | |
| 5/27/2015 | Robert Alexander Ingram | Director | Sell | 1,379 | $513.39 | $707,964.81 | |
| 5/26/2015 | Plew Daniel P Van | SVP | Sell | 18,370 | $508.42 | $9,339,675.40 | |
| 5/22/2015 | Douglas S Mccorkle | VP | Sell | 13,000 | $515.60 | $6,702,800.00 | |
| 5/22/2015 | Joseph L Goldstein | Director | Sell | 4,000 | $514.28 | $2,057,120.00 | |
| 5/15/2015 | Michael S Brown | Director | Sell | 5,000 | $495.00 | $2,475,000.00 | |
| 3/25/2015 | Charles A Baker | Director | Sell | 5,000 | $454.96 | $2,274,800.00 | |
| 3/24/2015 | Michael S Aberman | SVP | Sell | 4,843 | $478.99 | $2,319,748.57 | |
| 3/18/2015 | Michael S Aberman | SVP | Sell | 3,442 | $465.00 | $1,600,530.00 | |
| 3/17/2015 | Robert J Terifay | SVP | Sell | 10,993 | $451.01 | $4,957,952.93 | |
| 3/16/2015 | Joseph J Larosa | SVP | Sell | 18,311 | $450.00 | $8,239,950.00 | |
| 2/27/2015 | Douglas S Mccorkle | VP | Sell | 3,000 | $416.24 | $1,248,720.00 | |
| 2/26/2015 | Marc Tessier-Lavigne | Director | Sell | 3,000 | $421.95 | $1,265,850.00 | |
| 2/24/2015 | Robert J Terifay | SVP | Sell | 11,173 | $423.67 | $4,733,664.91 | |
| 2/23/2015 | Plew Daniel P Van | SVP | Sell | 9,431 | $427.82 | $4,034,770.42 | |
| 2/20/2015 | Joseph L Goldstein | Director | Sell | 5,000 | $423.65 | $2,118,250.00 | |
| 2/17/2015 | Michael S Aberman | SVP | Sell | 3,692 | $404.46 | $1,493,266.32 | |
| 1/2/2015 | Leonard S Schleifer | CEO | Sell | 1,500 | $410.58 | $615,870.00 | |
| 1/2/2015 | Peter Powchik | SVP | Sell | 10,822 | $414.08 | $4,481,173.76 | |
| 12/24/2014 | Sanofi | Major Shareholder | Buy | 201,459 | $393.21 | $79,215,693.39 | |
| 12/16/2014 | Douglas S Mccorkle | VP | Sell | 8,486 | $410.15 | $3,480,532.90 | |
| 11/24/2014 | Alfred G Gilman | Director | Sell | 40,000 | $408.44 | $16,337,600.00 | |
| 11/24/2014 | Neil Stahl | SVP | Sell | 5,307 | $412.93 | $2,191,419.51 | |
| 11/18/2014 | Robert J Terifay | SVP | Sell | 22,362 | $405.79 | $9,074,275.98 | |
| 11/13/2014 | Plew Daniel P Van | SVP | Sell | 8,575 | $399.34 | $3,424,340.50 | |
| 11/12/2014 | Joseph L Goldstein | Director | Sell | 5,000 | $398.31 | $1,991,550.00 | |
| 11/12/2014 | Leonard S Schleifer | CEO | Sell | 45,817 | $400.30 | $18,340,545.10 | |
| 10/28/2014 | Leonard S Schleifer | CEO | Sell | 69,112 | $404.01 | $27,921,939.12 | |
| 10/24/2014 | Michael S Brown | Director | Sell | 5,000 | $399.00 | $1,995,000.00 | |
| 10/24/2014 | Murray A Goldberg | SVP | Sell | 26,788 | $400.70 | $10,733,951.60 | |
| 9/16/2014 | Sanofi | Major Shareholder | Buy | 31,717 | $349.26 | $11,077,479.42 | |
| 9/15/2014 | Sanofi | Major Shareholder | Buy | 140,632 | $345.15 | $48,539,134.80 | |
| 9/10/2014 | P Roy Vagelos | Chairman | Sell | 10,328 | $350.07 | $3,615,522.96 | |
| 8/27/2014 | Joseph L Goldstein | Director | Sell | 2,000 | $350.31 | $700,620.00 | |
| 8/19/2014 | Michael S Aberman | VP | Sell | 3,611 | $350.00 | $1,263,850.00 | |
| 8/18/2014 | Douglas S Mccorkle | VP | Sell | 5,875 | $353.00 | $2,073,875.00 | |
| 8/15/2014 | Michael S Brown | Director | Sell | 3,000 | $349.20 | $1,047,600.00 | |
| 8/14/2014 | Joseph L Goldstein | Director | Sell | 2,000 | $347.65 | $695,300.00 | |
| 8/13/2014 | P Roy Vagelos | Chairman | Sell | 8,028 | $340.01 | $2,729,600.28 | |
| 8/11/2014 | Neil Stahl | SVP | Sell | 11,646 | $339.96 | $3,959,174.16 | |
| 8/11/2014 | P Roy Vagelos | Chairman | Sell | 11,972 | $340.11 | $4,071,796.92 | |
| 8/8/2014 | Neil Stahl | SVP | Sell | 2,841 | $340.60 | $967,644.60 | |
| 8/7/2014 | Plew Daniel P Van | SVP | Sell | 6,806 | $338.37 | $2,302,946.22 | |
| 8/6/2014 | Joseph L Goldstein | Director | Sell | 2,000 | $331.20 | $662,400.00 | |
| 7/15/2014 | Sanofi | Major Shareholder | Buy | 129,100 | $314.92 | $40,656,172.00 | |
| 7/14/2014 | Sanofi | Major Shareholder | Buy | 300,000 | $316.80 | $95,040,000.00 | |
| 7/10/2014 | Sanofi | Major Shareholder | Buy | 175,000 | $311.08 | $54,439,000.00 | |
| 7/9/2014 | Sanofi | Major Shareholder | Buy | 348,000 | $309.76 | $107,796,480.00 | |
| 7/7/2014 | Sanofi | Major Shareholder | Buy | 356,700 | $312.37 | $111,422,379.00 | |
| 7/2/2014 | Sanofi | Major Shareholder | Buy | 212,400 | $307.25 | $65,259,900.00 | |
| 7/1/2014 | Sanofi | Major Shareholder | Buy | 212,400 | $300.20 | $63,762,480.00 | |
| 6/30/2014 | Sanofi | Major Shareholder | Buy | 262,400 | $281.17 | $73,779,008.00 | |
| 5/23/2014 | Plew Daniel Van | SVP | Sell | 5,369 | $295.93 | $1,588,848.17 | |
| 5/19/2014 | Sanofi | major shareholder | Buy | 190,751 | $300.04 | $57,232,930.04 | |
| 3/28/2014 | Sanofi | major shareholder | Buy | 306,945 | $306.73 | $94,149,239.85 | |
| 3/27/2014 | Sanofi | major shareholder | Buy | 306,945 | $311.01 | $95,462,964.45 | |
| 3/24/2014 | Charles Baker | Director | Sell | 15,000 | $302.67 | $4,540,050.00 | |
| 3/24/2014 | Sanofi | major shareholder | Buy | 306,945 | $307.91 | $94,511,434.95 | |
| 3/21/2014 | Sanofi | major shareholder | Buy | 305,115 | $321.22 | $98,009,040.30 | |
| 3/20/2014 | Sanofi | major shareholder | Buy | 67,703 | $328.33 | $22,228,925.99 | |
| 3/17/2014 | Michael Brown | Director | Sell | 2,000 | $334.29 | $668,580.00 | |
| 3/17/2014 | Sanofi | major shareholder | Buy | 115,711 | $328.46 | $38,006,435.06 | |
| 3/12/2014 | Sanofi | major shareholder | Buy | 220,995 | $334.69 | $73,964,816.55 | |
| 3/11/2014 | Sanofi | major shareholder | Buy | 380,532 | $330.41 | $125,731,578.12 | |
| 3/7/2014 | Sanofi | major shareholder | Buy | 150,277 | $328.72 | $49,399,055.44 | |
| 3/3/2014 | Sanofi | major shareholder | Buy | 251,594 | $338.12 | $85,068,963.28 | |
| 2/27/2014 | Michael Brown | Director | Sell | 1,000 | $335.00 | $335,000.00 | |
| 2/25/2014 | Joseph Goldstein | Director | Sell | 1,000 | $338.86 | $338,860.00 | |
| 2/25/2014 | Murray Goldberg | SVP | Sell | 11,871 | $339.55 | $4,030,798.05 | |
| 2/21/2014 | Alfred Gilman | Director | Sell | 5,000 | $340.00 | $1,700,000.00 | |
| 2/21/2014 | Murray Goldberg | SVP | Sell | 21,258 | $336.51 | $7,153,529.58 | |
| 2/20/2014 | Joseph Goldstein | Director | Sell | 1,000 | $326.99 | $326,990.00 | |
| 2/18/2014 | Michael Aberman | VP | Sell | 3,648 | $331.42 | $1,209,020.16 | |
| 2/18/2014 | Robert Terifay | SVP | Sell | 12,865 | $332.68 | $4,279,928.20 | |
| 2/13/2014 | Neil Stahl | SVP | Sell | 22,612 | $318.82 | $7,209,157.84 | |
| 2/12/2014 | George Yancopoulos | Insider | Sell | 88,987 | $320.33 | $28,505,205.71 | |
| 2/12/2014 | Joseph Goldstein | Director | Sell | 1,000 | $320.62 | $320,620.00 | |
| 2/11/2014 | Alfred Gilman | Director | Sell | 5,000 | $320.00 | $1,600,000.00 | |
| 2/11/2014 | Douglas Mccorkle | VP | Sell | 5,819 | $325.00 | $1,891,175.00 | |
| 2/11/2014 | P Roy Vagelos | Chairman | Sell | 11,475 | $325.10 | $3,730,522.50 | |
| 2/7/2014 | Sanofi | major shareholder | Buy | 168,511 | $286.78 | $48,325,584.58 | |
| 2/5/2014 | Sanofi | major shareholder | Buy | 397,264 | $284.12 | $112,870,647.68 | |
| 2/3/2014 | Sanofi | major shareholder | Buy | 208,972 | $283.78 | $59,302,074.16 | |
| 1/28/2014 | Sanofi | major shareholder | Buy | 157,920 | $275.90 | $43,570,128.00 | |
| 1/14/2014 | Alfred Gilman | Director | Sell | 5,000 | $300.00 | $1,500,000.00 | |
| 1/14/2014 | Douglas Mccorkle | VP | Sell | 4,000 | $290.00 | $1,160,000.00 | |
| 1/2/2014 | Peter Powchik | SVP | Sell | 20,668 | $274.77 | $5,678,946.36 | |
| 12/20/2013 | Peter Powchik | SVP | Sell | 9,133 | $270.21 | $2,467,827.93 | |
| 11/26/2013 | George Sing | Director | Sell | 10,000 | $295.00 | $2,950,000.00 | |
| 11/6/2013 | Joseph Goldstein | Director | Sell | 1,000 | $300.74 | $300,740.00 | |
| 9/19/2013 | Leonard Schleifer | CEO | Sell | 102,949 | $302.67 | $31,159,573.83 | |
| 9/19/2013 | P Roy Vagelos | Chairman | Sell | 145,356 | $302.86 | $44,022,518.16 | |
| 9/18/2013 | Plew Daniel Van | SVP | Sell | 23,977 | $303.17 | $7,269,107.09 | |
| 9/18/2013 | William Roberts | VP | Sell | 15,000 | $304.00 | $4,560,000.00 | |
| 9/9/2013 | Leonard S Schleifer | CEO | Sell | 5,000 | $275.47 | $1,377,350.00 | |
| 8/23/2013 | Joseph Goldstein | Director | Sell | 1,000 | $238.29 | $238,290.00 | |
| 6/10/2013 | Charles A Baker | Director | Sell | 15,000 | $251.84 | $3,777,600.00 | |
| 5/31/2013 | Arthur F Ryan | Director | Sell | 2,500 | $249.55 | $623,875.00 | |
| 5/28/2013 | Joseph L Goldstein | Director | Sell | 4,000 | $252.20 | $1,008,800.00 | |
| 5/21/2013 | Murray A Goldberg | CFO | Sell | 66,835 | $259.74 | $17,359,722.90 | |
| 5/17/2013 | Michael S Brown | Director | Sell | 15,000 | $275.19 | $4,127,850.00 | |
| 5/14/2013 | Michael S Aberman | VP | Sell | 5,529 | $279.61 | $1,545,963.69 | |
| 5/13/2013 | Neil Stahl | SVP | Sell | 23,038 | $276.88 | $6,378,761.44 | |
| 5/10/2013 | George L Sing | Director | Sell | 5,000 | $270.00 | $1,350,000.00 | |
| 5/8/2013 | Robert J Terifay | SVP | Sell | 8,231 | $261.23 | $2,150,184.13 | |
| 5/6/2013 | P Roy Vagelos | Chairman | Sell | 12,018 | $263.15 | $3,162,536.70 | |
| 11/27/2012 | P Roy Vagelos | Chairman | Sell | 64,753 | $175.22 | $11,346,020.66 | |
| 11/26/2012 | Charles A Baker | Director | Sell | 15,000 | $173.87 | $2,608,050.00 | |
| 11/14/2012 | Michael S Brown | Director | Sell | 7,000 | $147.03 | $1,029,210.00 | |
| 11/1/2012 | Arthur F Ryan | Director | Sell | 10,000 | $145.57 | $1,455,700.00 | |
| 9/6/2012 | Charles A Baker | Director | Sell | 15,000 | $150.00 | $2,250,000.00 | |
| 8/23/2012 | George L Sing | Director | Sell | 10,000 | $140.50 | $1,405,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Regeneron Pharmaceuticals (NASDAQ:REGN)
Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Expect Regeneron Pharmaceuticals, Inc. (REGN) to Announce $3.86 Earnings Per Share
www.americanbankingnews.com - September 26 at 10:10 AM |
 | Notable Monday Option Activity: REGN, WHR, QRVO - Nasdaq
www.nasdaq.com - September 25 at 4:00 PM |
 | Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer
finance.yahoo.com - September 25 at 4:00 PM |
| Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 22 at 3:56 PM |
| ETFs with exposure to Regeneron Pharmaceuticals, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 3:56 PM |
| Regeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $500.00 by Analysts at UBS AG
www.americanbankingnews.com - September 21 at 3:44 PM |
 | Regeneron's Biggest Long-Term Opportunity - Barron's
www.barrons.com - September 20 at 8:19 AM |
 | Regeneron - Diversification Efforts Could Soon Yield Results - Seeking Alpha
seekingalpha.com - September 20 at 8:19 AM |
| [$$] Regeneron's Biggest Long-Term Opportunity
finance.yahoo.com - September 20 at 8:19 AM |
| Canaccord Genuity Reaffirms Buy Rating for Regeneron Pharmaceuticals, Inc. (REGN)
www.americanbankingnews.com - September 17 at 10:22 PM |
| Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
finance.yahoo.com - September 17 at 7:20 AM |
| Regeneron Pharmaceuticals, Inc. (REGN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 8:40 PM |
| Analysts’ Recommendations for Regeneron in September 2017
finance.yahoo.com - September 15 at 11:18 PM |
| Regeneron Is Focused on Increasing Awareness for Eylea in 2017
finance.yahoo.com - September 15 at 11:18 PM |
| Eylea Leads the Retinal Diseases Sector
finance.yahoo.com - September 15 at 11:18 PM |
| Swoop In To Pick Up Regeneron This Month - Seeking Alpha
seekingalpha.com - September 15 at 8:07 AM |
| Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis
finance.yahoo.com - September 15 at 8:07 AM |
| Regeneron Pharmaceuticals, Inc. (REGN) Now Covered by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM |
| Regeneron's Delivery Isn't Matching the Hype
finance.yahoo.com - September 14 at 1:49 AM |
| Oversold Conditions For Regeneron Pharmaceuticals (REGN) - Nasdaq
www.nasdaq.com - September 13 at 8:43 PM |
| Regeneron's Frustrating Month: Analysis And Commentary - Seeking Alpha
seekingalpha.com - September 13 at 8:18 AM |
| Sanofi indicates dupilumab could be used to treat nasal polyps
finance.yahoo.com - September 13 at 8:18 AM |
| Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
finance.yahoo.com - September 13 at 8:18 AM |
| 5 Things Regeneron's CEO Said as the Biotech Stock Sank
finance.yahoo.com - September 12 at 9:07 AM |
| Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Credit Suisse Group
www.americanbankingnews.com - September 11 at 3:50 PM |
 | Sanofi: Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
www.finanznachrichten.de - September 11 at 6:20 AM |
| Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial
www.nasdaq.com - September 11 at 6:20 AM |
| Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
finance.yahoo.com - September 11 at 6:20 AM |
| Sanofi and Regeneron announce positive dupilumab topline results
finance.yahoo.com - September 11 at 6:20 AM |
| Sanofi and Regeneron score asthma hit with dupilumab
finance.yahoo.com - September 11 at 6:20 AM |
| Regeneron Pharmaceuticals' (REGN) Buy Rating Reaffirmed at Citigroup Inc.
www.americanbankingnews.com - September 10 at 12:34 AM |
| Robert W. Baird Reiterates "Sell" Rating for Regeneron Pharmaceuticals Inc (REGN)
www.americanbankingnews.com - September 9 at 5:38 PM |
| Regeneron's Cemiplimab Gains Breakthrough Therapy Status
finance.yahoo.com - September 9 at 7:49 AM |
| Regeneron Pharmaceuticals, Inc. (REGN) Expected to Post Quarterly Sales of $1.46 Billion
www.americanbankingnews.com - September 9 at 1:30 AM |
| Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
www.nasdaq.com - September 8 at 7:36 AM |
| Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
finance.yahoo.com - September 8 at 7:35 AM |
| Why Regeneron (REGN) Could Be Positioned for a Surge
finance.yahoo.com - September 7 at 8:15 AM |
| Regeneron Pharmaceuticals Ready to Make All-Time Highs
finance.yahoo.com - September 7 at 8:15 AM |
| VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug
finance.yahoo.com - September 7 at 8:15 AM |
| Robert E. Landry Sells 189 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock
www.americanbankingnews.com - September 6 at 9:16 PM |
| Robert E. Landry Sells 663 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock
www.americanbankingnews.com - September 6 at 8:28 PM |
| Raymond James Financial, Inc. Reaffirms "Outperform" Rating for Regeneron Pharmaceuticals, Inc. (REGN)
www.americanbankingnews.com - September 6 at 10:49 AM |
| Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : September 1, 2017
finance.yahoo.com - September 2 at 8:01 AM |
| Robert E. Landry Sells 427 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock
www.americanbankingnews.com - September 1 at 8:04 PM |
| Regeneron Pharmaceuticals Witnessed Solid Growth in 2Q17
finance.yahoo.com - August 30 at 8:30 AM |
| How Did Regeneron’s Eylea and Praluent Perform in 2Q17?
finance.yahoo.com - August 30 at 8:30 AM |
| Dupixent and Kevzara: Regeneron’s Long-Term Growth Drivers?
finance.yahoo.com - August 30 at 8:30 AM |
| Regeneron Pharmaceuticals, Inc. (REGN) Major Shareholder Sanofi Purchases 72,378 Shares
www.americanbankingnews.com - August 29 at 7:16 PM |
| Regeneron Pharmaceuticals, Inc. (REGN) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - August 27 at 6:12 PM |
| Novartis hopeful for novel heart drug, despite 'modest' benefit
finance.yahoo.com - August 27 at 6:23 AM |
Regeneron Pharmaceuticals (REGN) Chart for Tuesday, September, 26, 2017
